Medindia

X

EPEMED, the European Personalised Medicine Association, Appoints Executive Director

Thursday, June 3, 2010 Corporate News J E 4
Advertisement
PARIS, June 3, 2010 The personalised medicine associationEPEMED, a European not-for-profit organisation bringing together globalforces in personalised medicine, has today announced the appointment of Dr.Anne Bruinvels, an entrepreneur in personalised healthcare, as ExecutiveDirector and board member. Dr. Bruinvels will be responsible for growing thestart-up organisation and, together with the board of directors, for buildingits strategic framework in creating guidance for all those involved inprogressing personalised medicine with an emphasis on European marketchallenges.

"I'm very pleased with the appointment of Dr. Anne Bruinvels as ExecutiveDirector and board member of EPEMED," said Alain Huriez, MD, Founder andPresident of EPEMED. "Her proven leadership and communication skills in thepersonalised medicine field will benefit the association greatly and I lookforward to working with her to bring harmonisation and education to thepersonalised medicine field in Europe. "

Dr. Anne Bruinvels stated, "I'm delighted to join EPEMED's board and tolead the association to facilitate the development and introduction ofpersonalised medicine in Europe. I'm looking forward to working with thedifferent parties worldwide involved in making real progress in this field."

To date, Europe is faced with a number of challenges to successfullydevelop innovative and effective, personalised medicine treatments. EPEMED'sobjectives are to develop

Dr. Bruinvels started her work in personalised medicine more than 10years ago. She has previously founded Elixior, a personalised healthcareadvisory company and prior to that Curidium, a personalised medicine companyidentifying companion diagnostics and therapeutics to treat patients withcentral nervous system disorders. She was Curidium's CEO for more than sixyears and raised several rounds of funding before taking the company publicon the AIM of the London Stock Exchange. Anne Bruinvels has also worked inresearch for various pharmaceutical companies, including SmithKline Beecham,Wyeth and Sandoz Pharma. She obtained her PhD (neuroscience) from UtrechtUniversity (the Netherlands) and her MSc (pharmacy) from Groningen University(The Netherlands).

EPEMED is a recently formed, not-for-profit organisation. The associationwas founded to address issues in personalised medicine that confront theindustry, regulators, payers & insurers as well as governments. EPEMED aimsto provide a platform for the harmonisation of personalised medicinedevelopment and implementation across Europe, focussing on the crucial roleof diagnostics, to make personalised medicine a reality. The organisation isdirected by a dynamic and diverse group of leaders in the personalisedmedicine field, who have great expertise in the application and developmentof diagnostic tools to deliver improved patient care.

About Personalised Medicine

Recent innovations in molecular diagnostics have played an important rolein improving patient outcomes in a range of human diseases. Jointly withpersonalised therapeutics, companion diagnostics form the field ofpersonalised medicine, where a person's clinical, genomic and environmentalinformation is used to more precisely select medication and dose for eachindividual patient. The application of personalised medicine is likely toimprove patient care as well as lower healthcare costs.

EPEMED (c) 2010. All rights reserved.1. A central point of communication for the different parties involved in progressing personalised medicine 2. Optimal routes to deliver personalised medicine treatments to patients 3. A greater understanding of the clinical development of personalised therapeutics through the creation and application of advanced diagnostic tests

SOURCE EPEMED
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Tianyin Corporate Presentation Updated
S
Pivotal Phase III Trial of Novartis Drug Afinitor®...